Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate ...

Only one out of 10,000 potential chemicals that are evaluated for drug discovery ever reach the market, and 40% of the compounds that begin animal trials will fail due to toxicity. Therefore, ...

From protein translation to mitosis, fundamental cellular processes are multifaceted and dynamic. Researchers seeking to understand the inner workings of a cell benefit from multidisciplinary ...

All cells within the same cancer are not the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical. In each cancer, there are populations of cells with ...

The early identification of antibody candidates with desired affinities and dissociation kinetics, binding epitopes and critical quality attributes is vital for avoiding later-phase failures caused by ...

The disposition of antibody-based therapeutics is generally determined by both target-mediated and non-target processes, the latter being an often-overlooked aspect. Target-independent liabilities can ...

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a ...